Archive for January, 2021

The market research report titled Cell Isolation Market by Product (Instruments and Consumables), by Cell Type (Animal and Human), by Cell Source (Adipose Tissue, Embryonic/Cord Blood Stem Cells, and Bone Marrow), by Technique (Surface Marker-Based Cell Isolation, Centrifugation-Based Cell Isolation, and Filtration-Based Cell Isolation), by Application (Cancer Research, Biomolecule Isolation, Tissue Regeneration & Regenerative Medicine, Stem Cell Research, In Vitro Diagnostics, and Others), and By End-User (Hospitals & Diagnostic Laboratories, Research Laboratories & Institutes, Biotechnology & Biopharmaceutical Companies, and Others): Global Industry Perspective, Comprehensive Analysis, and Forecast, 20182025 published by Zion Market Research provides an insightful comprehension about the growth aspects, dynamics, and working of the globalCell IsolationMarket. The report entails details about the market with data collected over the years with its wide-ranging analysis. It also comprises the competitive landscape within the market together with a detailed evaluation of the leading players within the global Cell Isolation Market. In addition, it sheds light on the profiles of the key vendors/manufacturers comprising thorough assessment of the market share, production technology, market entry strategies, revenue forecasts, and so on. Further, the report will encompass the fundamental strategic activities such as product developments, mergers & acquisitions, launches, events, partnerships, collaborations, and so on. Apart from this, it will also present the new entrants contributing their part in the market growth.

FREE | Request Sample is Available @https://www.zionmarketresearch.com/sample/cell-isolation-market

Global Cell Isolation Market: Competitive Players

Becton, Dickinson, and Company, Thermo Fisher Scientific, Inc., Merck KGaA, Beckman Coulter Inc., Terumo BCT, Bio-Rad Laboratories, Inc.

The Cell Isolation Market report also entails exhaustive examination of the key factors likely to propel or restrict the expansion of the global Cell Isolation Market during the forecast period in addition to the most recent and promising future trends in the market. Moreover, the report uses SWOT analysis and other methodologies to analyze the numerous segments [Product, Applications, End-Users, and Major Regions] of the global Cell Isolation Market. Furthermore, it comprises valuable understanding about the segments like their growth potential, market share, and developments. It also evaluates the market on the basis of its major geographical regions [Latin America, North America, Asia Pacific, Middle & East Africa, and Europe]. It entails quantitative and qualitative facets of the market in association to each country and region enlisted in the report.

Promising Regions & Countries Mentioned In The Cell Isolation Market Report:

Download Free PDF Report Brochure @https://www.zionmarketresearch.com/requestbrochure/cell-isolation-market

The Cell Isolation Market report also stipulates the computed expected CAGR of the market estimated on the basis of the existing and previous records concerning the global Cell Isolation Market. The report analyzes the market with the aim of being capable to get a clear picture of prevailing and anticipated growth patterns of the market. Furthermore, it entails the impact of numerous federal policies and rules on the growth and dynamics of the market during the forecast period. The thorough assessment put forth by our analysts assist to get more profound acquaintance of global markets and related industries. In addition, the report encompasses various tactics to discover the weaknesses, opportunities, risks, and strengths having the potential to impact the global market expansion.

Impact of COVID-19 (Coronavirus):The report will also entail a dedicated section assessing the influence of COVID-19 on the expansion of the global Cell Isolation Market during the coming period.

Report Customization:Clients can request for customization of report as per their need for additional data.

Apart from this, our team will be accessible around the clock to our clients for any kind of assistance.

Inquire more about this report @https://www.zionmarketresearch.com/inquiry/cell-isolation-market

Key Details & USPs of the Existing Report Study:

Request coronavirus impact analysis on sectors and market

Request Report TOC (Table of Contents) @https://www.zionmarketresearch.com/toc/cell-isolation-market

What Reports Provides

Also, Research Report Examines:

Thanks for reading this article;you can also get individual chapter wise section or region wise report version like North America, Europe or Asia.

Original post:
Global Cell Isolation Market SWOT Analysis, Key Indicators, Forecast 2027 : Becton, Dickinson, and Company, Thermo Fisher Scientific KSU | The...

The CRISPR systems inside bacteria serve as adaptive immune systems, but they also threaten to unleash autoimmune reactions. Fortunately, for bacteria such as Streptococcus pyogenes, these systems have a built-in safety feature: a long-form transactivating CRISPR RNA (tracrRNA). Unlike the short-form tracrRNA, which together with CRISPR RNA (crRNA) complexes with the CRISPR-Cas9 enzyme and guides it to DNA sites where it executes cuts, the long-form tracrRNA guides the enzyme to the enzymes own genetic promoter.

The long-form tracrRNA that complexes CRISPR-Cas9 enzyme doesnt need to bind to crRNA, and it doesnt cut. Instead, it merely lingers in place, preventing gene expression.

Essentially, long-form tracrRNA acts as a safety feature, dialing down a bacteriums immune system to prevent it from attacking the bacterium itself rather than foreign DNA. This self-protection function for long-form tracrRNA was uncovered by researchers at Johns Hopkins University. The researchers, led by Joshua W. Modell, PhD, also explored whether long-form tracrRNA could be reprogrammed to guide CRISPR-Cas9 to DNA sites other than the CRISPR-Cas9 promoter.

The researchers findings appeared in the journal Cell, in an article titled, A natural single-guide RNA repurposes Cas9 to autoregulate CRISPR-Cas expression. According to the researchers, long-form tracrRNA could serve as a programmable genetic dimmer switch, one that could be used to inhibit the expression of designated genes in research applications.

We show that in the S. pyogenes CRISPR-Cas system, a long-form transactivating CRISPR RNA folds into a natural single guide that directs Cas9 to transcriptionally repress its own promoter (Pcas), the articles authors wrote. Further, we demonstrate that Pcas serves as a critical regulatory node.

Scientists have long worked to unravel the precise steps of CRISPR-Cas9s mechanism and how its activity in bacteria is dialed up or down. Looking for genes that ignite or inhibit the CRISPR-Cas9 gene-cutting system for the common, strep-throat causing bacterium S. pyogenes, the Johns Hopkins scientists found a clue regarding how that aspect of the system works.

Specifically, the scientists found a gene in the CRISPR-Cas9 system that, when deactivated, led to a dramatic increase in the activity of the system in bacteria. The product of this gene appeared to re-program Cas9 to act as a brake, rather than as a scissor, to dial down the CRISPR system.

From an immunity perspective, bacteria need to ramp up CRISPR-Cas9 activity to identify and rid the cell of threats, but they also need to dial it down to avoid autoimmunitywhen the immune system mistakenly attacks components of the bacteria themselves, said graduate student Rachael Workman, a bacteriologist working in Modells laboratory.

To further nail down the particulars of the brake, the teams next step was to better understand the product of the deactivated gene, a tracrRNA. tracrRNAs belong to a unique family of RNAs that do not make proteins. Instead, they act as a kind of scaffold that allows the Cas9 enzyme to carry the guide RNA that contains a mug shot of previously encountered phage DNA. The mug shot allows Cas9 to cut matching DNA sequences in newly invading viruses.

tracrRNA comes in two sizes: long and short. Most of the modern gene-cutting CRISPR-Cas9 tools use the short form. However, the research team found that the deactivated gene product was the long-form of tracrRNA, the function of which has been entirely unknown.

In bacteria, DNA-cutting CRISPR-Cas9 complexes typically consist of a Cas9 enzyme and a guide RNA. The guide RNA consists of a short-form transactivating CRISPR RNA (tracrRNA) scaffold and a DNA-sequence-specific CRISPR (crRNA). Long-form tracrRNA, however, can complex with and guide Cas9 without crRNA. When long-form tracrRNA does so, it guides the Cas9 enzyme to a Cas9 promoter. The promoter is not cut, but expression is repressed. Left: A schematic of the long-form of the tracrRNA used by the CRISPR-Cas9 system in bacteria. Right: the standard guide RNA used by many scientists as part of the gene-cutting CRISPR-Cas9 system. (Often, the guide RNA is a single synthetic molecule, rather than a combination of tracrRNA and crRNA.) [Joshua Modell and Rachael Workman, Johns Hopkins Medicine]The long and short forms of tracrRNA are similar in structure and have in common the ability to bind to Cas9. The short-form tracrRNA also binds to the guide RNA. However, the long-form tracrRNA doesnt need to bind to the crRNA, because it contains a segment that mimics the crRNA. Essentially, long-form tracrRNAs have combined the function of the short-form tracrRNA and crRNA, explained Modell, assistant professor of molecular biology and genetics at the Johns Hopkins University School of Medicine.

The researchers used genetic engineering to alter the length of a certain region in long-form tracrRNA to make the tracrRNA appear more like a guide RNA. They found that with the altered long-form tracrRNA, Cas9 once again behaved more like a scissor.

Other experiments showed that in lab-grown bacteria with a plentiful amount of long-form tracrRNA, levels of all CRISPR-related genes were very low. When the long-form tracrRNA was removed from bacteria, however, expression of CRISPR-Cas9 genes increased a hundredfold.

Bacterial cells lacking the long-form tracrRNA were cultured in the laboratory for three days and compared with similarly cultured cells containing the long-form tracrRNA. By the end of the experiment, bacteria without the long-form tracrRNA had completely died off. De-repression causes a dramatic 3,000-fold increase in immunization rates against viruses, the articles authors noted. However, heightened immunity comes at the cost of increased autoimmune toxicity.

These findings suggest that long-form tracrRNA normally protects cells from the sickness and death that happen when CRISPR-Cas9 activity is very high. We started to get the idea that the long form was repressing but not eliminating its own CRISPR-related activity, recalled Workman.

To see if the long-form tracrRNA could be re-programmed to repress other bacterial genes, the research team altered the long-form tracrRNAs spacer region to let it sit on a gene that produces green fluorescence. Bacteria with this mutated version of long-form tracrRNA glowed less green than bacteria containing the normal long-form tracrRNA, suggesting that the long-form tracrRNA can be genetically engineered to dial down other bacterial genes.

Another research team, from Emory University, found that in the parasitic bacteria Francisella novicida, Cas9 behaves as a dimmer switch for a gene outside the CRISPR-Cas9 region. The CRISPR-Cas9 system in the Johns Hopkins study is more widely used by scientists as a gene-cutting tool, and the Johns Hopkins teams findings provide evidence that the dimmer action controls the CRISPR-Cas9 system in addition to other genes.

Using bioinformatic analyses, we provide evidence that tracrRNA-mediated autoregulation is widespread in type II-A CRISPR-Cas systems, the Johns Hopkins scientists added. Collectively, we unveil a new paradigm for the intrinsic regulation of CRISPR-Cas systems by natural single guides, which may facilitate the frequent horizontal transfer of these systems into new hosts that have not yet evolved their own regulatory strategies.

The researchers also found the genetic components of long-form tracrRNA in about 40% of the Streptococcus group of bacteria. Further study of bacterial strains that dont have the long-form tracrRNA, said Workman, will potentially reveal whether their CRISPR-Cas9 systems are intact, and other ways that bacteria may dial back the CRISPR-Cas9 system.

The dimmer capability that the experiments uncovered offers opportunities to design new or better CRISPR-Cas9 tools aimed at regulating gene activity for research purposes. In a gene editing scenario, Modell suggested, a researcher may want to cut a specific gene, in addition to using the long-form tracrRNA to inhibit gene activity.

Excerpt from:
Natural CRISPR's Safety Feature Could Become Genetic Dimmer Switch - Genetic Engineering & Biotechnology News

TipRanks

Big Tech has been in the news lately, and not necessarily for the right reasons. Accusations of corporate censorship have hit the headlines in recent weeks. While serious, this may have a salutary effect the public discussion of Big Techs role in our digital lives is long overdue. And that discussion will get underway just as the Q4 and full-year 2020 financial numbers start coming in. Of the FAANG stocks, Netflix has already reported; the other four will release results in the next two weeks. So, the upcoming earnings will garner well-deserved attention, and Wall Streets best analysts are already publishing their views on some of the markets most important components. Using TipRanks database, we pulled up the details on two members of the FAANG club to find out how the Street thinks each will fare when they publish their fourth quarter numbers. According to the platform, both have received plenty of love from the analysts, earning a Strong Buy consensus rating. Facebook (FB) Lets start with Facebook, the social media giant that has redefined our online interactions. Along with Google, Facebook has also brought us targeted digital marketing and advertising, and the mass monetization of the internet. Its been a profitable strategy for the company. Facebooks market cap is up to $786 billion, and in the third quarter of 2020, the company reported $21.5 billion at the top line. Looking ahead to the Q4 report, due out on January 27, analysts are forecasting revenues at or near $26.2 billion. This would be in-line with the companys pattern, of rising quarterly performance from Q1 to Q4. At the predicted sum, revenues would rise 24% year-over-year, roughly congruent with the 22% yoy gain already seen in Q3. The key metric to watch out for will be the growth in daily active users; this metric slipped slightly from Q2 to Q3, and further decline will be taken as an ominous sign for the companys future. As it stands now, Facebooks daily average user number is 1.82 billion. Ahead of the print, Oppenheimer analyst Jason Helfstein boosted his price target to $345 (from $300), while reiterating an Outperform (i.e. Buy) rating. Investors stand to pocket ~26% gain should the analyst's thesis play out. (To watch Helfsteins track record, click here) The 5-star analyst commented, "[We] anticipate 4Q advertising revenue will handily top Street estimates. We now forecast 4Q advertising revenue +30% y/y vs. Street's +25% estimate based on a regression of US Standard Media Index Data (r-squared 0.95) and accelerating global CPM data from Gupta Media (4Q +35% y/y vs. 3Q's -12%). Additionally, we are very bullish on FB's eCommerce opportunity following conversations with our checks and our initial work conservatively estimating Shops is a $2550B opportunity vs. current $85B revs. We believe shares currently trading at 7.1x EV/NTM sales offers the most favorable risk/ reward in internet large cap." Overall, the social media empire remains a Wall Street darling, as TipRanks analytics showcasing FB as a Strong Buy. This is based on 34 recent reviews, which break down to 30 Buy ratings, 3 Holds, and 1 Sell. Shares are priced at $276.10 and the average price target of $327.42 suggests a one-year upside of ~19%. (See FB stock analysis on TipRanks) Amazon (AMZN) Turning to e-commerce, we cant avoid Amazon. The retail giant has a market cap of $1.65 trillion, making it one of just four publicly traded companies valued over the trillion-dollar mark. The companys famously price is famously high, and has grown 74% since this time last year, far outpacing the broader markets. Amazons growth has been supported by increased online sales activity during the corona year. Globally, online retail has grew 27% in 2020, while total retail slipped 3%. Amazon, which dominates the online retail sector, is projected to end 2020 with $380 billion in total revenue, or 34% year-over-year growth, outpacing the global e-commerce gains. Cowen analyst John Blackledge, rating 5-stars by TipRanks, covers Amazon and is bullish on the companys prospects ahead of the earnings release. Blackledge rates the stock Outperform (i.e. Buy), and his price target, at $4,350, indicates confidence in a 31% upside on the one-year time horizon. (To watch Blackledges track record, click here) We forecast 4Q20 reported revenue of $120.8BN, +38.2% y/y vs. +37.4% y/y in 3Q20 led by AWS, advertising, subscription and 3P sales [..] We estimate US Prime sub growth accelerated in 4Q20 (reaching 76MM subs in Dec '20 and ~74MM on avg in 4Q20), helped by pandemic demand, Prime Day in Oct, & elongated shopping period, as well as 1 Day delivery [...] In '21, we expect strong top-line growth to continue driven by eCommerce (helped by COVID pull forward in Grocery), adv., AWS & sub businesses," Blackledge opined. That Wall Street generally is bullish on Amazon is no secret; the company has 33 reviews on record, and 32 of them are Buys, versus 1 Hold. Shares are priced at $3,301.26 and the average price target of $3,826 implies that it will grow another 16% this year. (See AMZN stock analysis on TipRanks) To find good ideas for stocks trading at attractive valuations, visit TipRanks Best Stocks to Buy, a newly launched tool that unites all of TipRanks equity insights. Disclaimer: The opinions expressed in this article are solely those of the featured analysts. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.

See the rest here:
CRISPR (CRSP) Up More Than 80% in Past 3 Months: Here's Why - Yahoo Finance

For Immediate Release

Chicago, IL January 20, 2021 Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: CRISPR Therapeutics AG CRSP, Vertex Pharmaceuticals Incorporated VRTX and Intellia Therapeutics, Inc. NTLA.

Shares ofCRISPR Therapeutics have rallied 87.3% in the past three months compared with theindustry'sincrease of 15.4%.

The company has made rapid progress with the development of its lead pipeline candidate, CTX001. The candidate is an investigational ex vivo CRISPR gene-edited therapy, which is currently being developed for treating sickle cell disease ("SCD") and transfusion-dependent beta thalassemia ("TDT") in partnership withVertex Pharmaceuticals.

In December 2020, the companiesannouncedpromising additional data on CTX001, which demonstrated a consistent and sustained response in treating patients with SCD and TDT. Treatment with CTX001 showed that all seven patients with TDT remained transfusion independent until the last follow-up, while all three patients with SCD were free of vaso-occlusive crises through the last follow-up.

Both diseases have a significant unmet medical need, and if successfully developed and commercialized, the candidate can lend a huge boost to CRISPR Therapeutics' prospects.

Notably, CTX001 has been granted Regenerative Medicine Advanced Therapy, Fast Track, and Orphan Drug designations by the FDA for both TDT and SCD. The European Commission has granted Orphan Drug Designation to the gene therapy candidate for both indications.

Genomic editing to repair a defective genetic material that causes diseases using CRISPR technology is probably one of the most promising and exciting healthcare innovations seen in decades. The technology has the potential to change how diseases, especially those caused by genetic mutations, are treated.

Story continues

Though the market holds great potential, competition remains stiff in the space. Other companies likeIntellia Therapeutics are also engaged in developing candidates to address different indications using CRISPR/Cas9 gene-editing technology.

CRISPR Therapeutics is also developing three gene-edited allogeneic cell therapy programs, chimeric antigen receptor T cell (CAR-T) candidates, CTX110, CTX120 and CTX130 for the treatment of hematological and solid tumor cancers. Several data readouts on the above candidates are expected in the ongoing year and a positive outcome might drive the stock further up in the days ahead.

CRISPR Therapeutics currently carries a Zacks Rank #3 (Hold). You can seethe complete list of today's Zacks #1 Rank (Strong Buy) stocks here.

Each was hand-picked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2020. Each comes from a different sector and has unique qualities and catalysts that could fuel exceptional growth.

Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor.

Today, See These 5 Potential Home Runs >>

Media Contact

Zacks Investment Research

800-767-3771 ext. 9339

support@zacks.com

https://www.zacks.com

Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumedthat any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein andis subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free reportVertex Pharmaceuticals Incorporated (VRTX) : Free Stock Analysis ReportIntellia Therapeutics, Inc. (NTLA) : Free Stock Analysis ReportCRISPR Therapeutics AG (CRSP) : Free Stock Analysis ReportTo read this article on Zacks.com click here.Zacks Investment Research

See the rest here:
The Zacks Analyst Blog Highlights: CRISPR Therapeutics, Vertex Pharmaceuticals and Intellia Therapeutics - Yahoo Finance

Generally speaking, investors are inspired to be stock pickers by the potential to find the big winners. Not every pick can be a winner, but when you pick the right stock, you can win big. One such superstar is CRISPR Therapeutics AG (NASDAQ:CRSP), which saw its share price soar 411% in three years. On top of that, the share price is up 115% in about a quarter.

Check out our latest analysis for CRISPR Therapeutics

CRISPR Therapeutics wasn't profitable in the last twelve months, it is unlikely we'll see a strong correlation between its share price and its earnings per share (EPS). Arguably revenue is our next best option. Generally speaking, companies without profits are expected to grow revenue every year, and at a good clip. Some companies are willing to postpone profitability to grow revenue faster, but in that case one does expect good top-line growth.

CRISPR Therapeutics' revenue trended up 81% each year over three years. That's much better than most loss-making companies. In light of this attractive revenue growth, it seems somewhat appropriate that the share price has been rocketing, boasting a gain of 72% per year, over the same period. Despite the strong run, top performers like CRISPR Therapeutics have been known to go on winning for decades. In fact, it might be time to put it on your watchlist, if you're not already familiar with the stock.

The company's revenue and earnings (over time) are depicted in the image below (click to see the exact numbers).

CRISPR Therapeutics is a well known stock, with plenty of analyst coverage, suggesting some visibility into future growth. So it makes a lot of sense to check out what analysts think CRISPR Therapeutics will earn in the future (free analyst consensus estimates)

Pleasingly, CRISPR Therapeutics' total shareholder return last year was 241%. So this year's TSR was actually better than the three-year TSR (annualized) of 72%. The improving returns to shareholders suggests the stock is becoming more popular with time. While it is well worth considering the different impacts that market conditions can have on the share price, there are other factors that are even more important. Case in point: We've spotted 3 warning signs for CRISPR Therapeutics you should be aware of.

If you would prefer to check out another company -- one with potentially superior financials -- then do not miss this free list of companies that have proven they can grow earnings.

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on US exchanges.

PromotedIf you decide to trade CRISPR Therapeutics, use the lowest-cost* platform that is rated #1 Overall by Barrons, Interactive Brokers. Trade stocks, options, futures, forex, bonds and funds on 135 markets, all from a single integrated account.

This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. *Interactive Brokers Rated Lowest Cost Broker by StockBrokers.com Annual Online Review 2020

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

Go here to read the rest:
Investors Who Bought CRISPR Therapeutics (NASDAQ:CRSP) Shares Three Years Ago Are Now Up 411% - Simply Wall St

Sickle cell anemia and thalassemia are genetic diseases that result in the production of anomalous hemoglobin (protein that carries oxygen) and deformed red blood cells. There is no cure for these ailments, but ten patients who have had their genes edited are on their way to get rid of them, thanks to the Clustered Regularly Interspaced Short Palindromic Repeats technique or CRISPR.

It is possible to edit human cells and safely infuse them in patients; this treatment has totally changed their lives, said haematologist Haydar Frangoul of the Sarah Cannon Research Institute. He is the doctor accompanying the studys first volunteer, the housewife and mother of three children Victoria Gray.

The work consisted of activating the generation of fetal hemoglobin, which is still produced in the womb and which results in healthy red blood cells. When the baby is born, the gene turns off and, in patients with thalassemia and sickle cell anemia, the result is the production of anomalous hemoglobin.

To receive the stem cells edited by CRISPR, patients first had to go through a painful stage: numerous rounds of chemotherapyAfter all the stem cells that produced the anomalous hemoglobin were destroyed, those edited were infused into the patients to reproduce and manufacture fetal hemoglobin.

Read the original post

Read more:
We may have a CRISPR cure for red blood diseases sickle cell anemia and beta thalassemia - Genetic Literacy Project

The genomics space is rapidly innovating. The ARK Genomic Revolution Multi-Sector Fund (CBOE: ARKG) makes accessing innovation much easier.

For investors, ARKGs active management and utility are vital because the fund is flexible and able to capitalize on genomics advancements more rapidly than index-based rivals. Those advancements include gene editing.

Crispr-Cas9 is the second generation of technologies that seek to repair thousands of inherited genetic disorders and battle cancer in new ways. Gene editing is advancing so quickly that next-generation technologies are already on the heels of Crispr-Cas9, including a more-precise tool called base editing, reports Bill Alpert for Barrons.

The CRISPR technology may also be under the spotlight as another disease fighting tool, with the world refocusing on the need for improved healthcare solutions.

The ARK Genomic Revolution ETF tracks the convergence of tech and healthcare. The underlying components are expected to substantially benefit from extending and enhancing the quality of human and other life by incorporating technological and scientific developments and advancements in genomics into their business.

While gene-editing start-ups will lose money during years of clinical trials, its hard to say the stocks are overvalued. If their one-time interventions can cure diseases that otherwise require chronic treatmentor lack any treatment at allthen the stocks will fly, according to Barrons.

That speaks to a big advantage with ARKG: investors dont have to stock pick in the gene editing arena.

Looking ahead, CRISPR-based innovations to accelerate given the technologys ease of use, cost-efficacy, a growing body of research surrounding its safety, and AI-powered CRISPR nuclease selection tools. CRISPR could also be utilized to address some of the most prominent healthcare problems, which opens up a significant investment opportunity in monogenic diseases.

CRISPR can cut DNA/RNA at a single point or in stretches; insert DNA/RNA and create novel gene sequences; activate and silence genes without making permanent changes; regulate protein expression levels epigenetically; record and timestamp biological events; track the movement of specific biological molecules; identify the presence of specific cancer mutations and bacteria; locate molecules without making changes; target and destroy specific viral and bacterial DNA and RNA; interrogate gene function multiplexed, and activate drug release at a specified trigger.

Because gene editing permanently changes the genome, it doesnt appear to suffer from these issues. Nature evolved many tools to cut DNA at specific spots in the genome, addsBarrons.

For more on disruptive technologies, visit our Disruptive Technology Channel.

The opinions and forecasts expressed herein are solely those of Tom Lydon, and may not actually come to pass. Information on this site should not be used or construed as an offer to sell, a solicitation of an offer to buy, or a recommendation for any product.

Go here to read the rest:
The ARKG ETF: Join the Genomics Revolution - ETF Trends

Once the UK left the EU, it would be free to invest in gene editing of crops and livestock to feed the world. Thats what the prime minister, Boris Johnson, told the House of Commons in 2019. And following the UKs formal departure from the EU in January 2021, the government quickly launched a public consultation on the issue.

Yet media reporting might cause plant scientists to have unpleasant flashbacks to the 1990s, when genetically modified (or GM) crops were first being commercialised in Europe. Some of the language used to report on the consultation is eerily similar: the Daily Mail asks its readers whether Frankenstein food is about to hit UK plates. Two decades ago, GM crops were also labelled Frankenfood.

Whereas GM crops typically contain the DNA of two different species, gene editing is more precise and allows scientists to tweak the DNA of a single species by itself. Today, many plant scientists see a clear difference between first-generation genetic modifications and the new plant breeding techniques of gene editing. These include tools like CRISPR, which can be used like genetic scissors to make changes to a plant that mimic natural variation.

In the US and Canada, for example, a non-browning mushroom has found a quick path to market thanks to breeders ability to knock-out the gene that controls the browning enzyme, improving shelf-life and potentially minimising food waste.

Although this was done in a laboratory, natural processes at the genetic level and in response to environmental conditions turn genes on and off in a similar fashion. These tools have health applications, too. CRISPR is being used to treat cancer and has the potential for many more medical applications.

Because gene-edited plants can be indistinguishable from their conventional cousins unlike GM crops countries around the world are grappling with how they should be regulated. In the European Union, a landmark 2018 ruling by the Court of Justice said that new gene-edited crops should be governed by existing legislation that was developed in response to first-generation GM crops and said that if you breed something that could not occur in nature, it counts as genetically-modified.

However, this does not mean as was widely reported that gene-edited crops are automatically GM crops, which by definition could not occur in nature. The EU, like the UK, is now revisiting this issue through a consultation.

As recipients of European plant science funding, we have seen that scientists and the public often talk past one another on the issue of biotechnology. Scientists, for their part, tend to view it in terms of risk (or lack thereof) and invoke humanitys long history of modifying plants for our own purposes. But we need to move beyond this framework and instead take account of the questions and concerns that the general public has about who benefits from this technology, who owns it and what impacts it will have.

First-generation genetic modification tended to focus on farm productivity. Protecting crops from pests was the top priority. Gene-edited crops could contribute to a wider variety of sustainability and health goals in future though, such as by improving nutrition or using resources more efficiently. In fact, a whole raft of technologies could be about to revolutionise the way we make food.

However, as we learned with GM crops, technologies are most effective when the wider public and key stakeholders, such as farmers, are actively included in their development.

There is greater and greater recognition among researchers and policymakers of the need to ensure that new technology meets the needs, expectations and values of the public. We have seen that the involvement of patients can make new health technologies more relevant and effective. Already, there is more talk of democratising new genomic tools like CRISPR.

So although plant scientists will hope to avoid repeating the same debates about biotechnology that they had two decades ago, there is still opportunity to gain public trust in these technologies through active and open dialogue. We must ask ourselves whether the gene editing consultation goes far enough to gain that trust, particularly for those that see this as Frankenstein-like technology.

Link:
Gene-edited crops are now a reality but will the public be on board? - The Conversation UK

As the air continues to dry and temperatures drop, the yearly battle against dry hands and skin has officially begun. New research from Northwestern University has discovered new evidence deep within the skin about the mechanisms controlling skin renewal and repair.

Skins barrier function gives it the unique ability to fight winter woes and keep water for our bodies. The outer layer of the skin, the skin, is constantly turning over to replace damaged or dead cells, creating new cells to reinforce the barrier function and heal damage. The gene regulatory mechanisms that control epidermis turnover remain incompletely understood.

Every month were covered with a new layer of the epidermis, said Northwesterns Xiaomin Bao, who headed the study. The next question is what does that procedure involve?

The newspaper will be published on Jan. 19 in the journal Nature Communications.

GeneticjunkThe scientific community has developed a wide breadth of knowledge about proteins, the workhorses of various cellular activities. Many mysteries remain about the nature of introns, non-coding segments of DNA that make up 24% of the human genome.

Regardless of the general belief that introns are nothing butgenetic junk, they actually play critical roles in modulating RNA transcription throughout a tissues lifespan. RNA transcription is the first step of gene expression, in which the data from DNA is copied into RNA, which is then subsequently used as a template for synthesizing proteins to drive the specific function of a cell.

Based on where transcription terminates within an intron or at the conclusion of a gene an epidermal stem cell will either remain a stem cell or become a specified cell barrier function. Bao said while its well-known that transcription ends at the end of a gene, her labs research found conflicting data.

Future research could have implications for carcinoma research.

Technology critical to the discovery of the phenomenonSkin cells are gaining popularity with researchers in part because of their regenerative properties and readiness to grow in cultures. This allows researchers to apply an assortment of state-of-the-art technologies. By growing skin cells and regenerating skin tissue in a petri dish, the Bao Lab can experiment with this fast-growing tissue to determine molecular mechanisms and regulatory elements within DNA.

Technology development is an integral driver that enabled us to uncover this new phenomenon, Bao said.

The group used a novel genomic technique that maps where transcription stops. The integration of proteomic approaches identified RNA-binding proteins which read specific regulatory sequences in the introns.

The team further leveraged CRISPR technologies to delete genomic sequences in the intron, which provided direct evidence demonstrating that the crucial roles of introns in modulating gene expression.

Before this study, mechanisms between introns to govern the switch between a skin stem cell and a terminally differential state (for example, a cell that participates in forming a skin barrier), were unknown. Most studies ignored introns, despite them accounting for 10 to 20 times more sequences than the protein-coding regions (exons) in the human genome.

The study demonstrates that different genes may involve different sets of RNA-binding proteins to recognize the regulatory sequences in their introns. These RNA-binding proteins help to mature RNAdecide whether to cut transcription early or dismiss termination sites within an intron during differentiation due to changes in protein availability.

We are only starting to appreciate the roles of the intron in human health and diseases, Bao said.

Results of this study could have broader impacts because, according to Bao, the procedures regulating skin cells are almost definitely not restricted to skin cells. Future research on other systems, including other epithelial tissues, will likely uncover similar patterns.

We are extremely hopeful that what weve found is the first step to knowing what we have ignored in the past, Bao said. My students also wish to know more about the RNA binding proteins which provide specificity in governing which site to use to terminate transcription.

Source:

Originally posted here:
Research finds new proof about the systems controlling skin repair and regeneration - Microbioz India

While the thought of dozens of tiny needles aimed directly at our faces sounds like a scare, microneedling may be worth it for the radiant skin it delivers. As with any trending procedure, it has its pros and consheres what four top doctors want you to know before scheduling an appointment.

It Opens Up the Skin BarrierMicroneedling creates little puncture sites in the skin, which allow for deeper product penetration, says Highland Park, IL plastic surgeon Steven P. Bloch, MD, who recommends combining the treatment with TCA peels that include hydrogen peroxide, exosomesthe healing, skin-calming growth factors derived from stem cellsor vitamins to stimulate collagen and elastin production. Applying medical-grade skin-care products after the procedure offers the best results because the skin will soak everything up much more effectively.

It Stimulates Collagen ProductionAs we age, our bodies produce less collagen (starting as early as our 20s), and therefore our skin begins to lose elasticity. However, Birmingham, AL dermatologist Corey Hartman, MD explains that microneedling promotes collagen production in our skin cells, helping it look as young as possible. Microneedling, which works on all skin types, administers small injuries to kick the bodys natural healing process into gear and rejuvenate the skin, he explains. Though there are only a few procedures in cosmetic dermatology that are truly preventive, microneedling delivers on the promise to stimulate fibroblasts, which synthesize the production of collagen.

ItCanBeEffectiveforTreatingMelasmaOne of the most common concerns women walk into our office with is melasma, says Grand Rapids, MI plastic surgeon Bradley Bengtson, MD. More often than not, melasma is not optimally treated with high-heat laser devices, so microneedling is a great tool to break up the pigment. The procedure banishes dark patches by allowing brightening creams and serums with ingredients like vitamin C to penetrate deep into the epidermal and dermal layers.

ItRequiresNoSkilltoUseAny Tom, Dick, Sally or Jane can buy a microneedling machine, set up a strip-mall shop and offer it to people, says Eagan, MN dermatologist Charles E. Crutchfield III, MD, who stresses that complications can arise if you dont visit a board-certified doctor for the treatment. Instead, he recommends an ablative laser, which also boosts collagen and tightens the skin with much more sophistication.

At NewBeauty, we get the most trusted information from the beauty authority delivered right to your inbox

Find a NewBeauty "Top Beauty Doctor" Near you

Read the original:
4 Doctors Reveal the Pros and Cons to Microneedling Treatments - NewBeauty Magazine

Body Shop stans, assemble! We have collated the best the brand has to offer to optimise your bathroom cabinet.

But before you start shopping, here are a few did you knows. This cruelty-free, British brand was the first international cosmetics brand to prohibit the use of ingredients tested on animals and one of the first to promote Fair Trade with third world countries. Earning its place as a household name over the past four decades plus a cult following, thanks to a diverse range of over 900 products, suitable for different skin tones and types and half of which are vegan.

For some insight, this Brighton-born beauty story dates back to 1976. It was founded by the iconic entrepreneur and human rights activist Dame Anita Roddick, pioneer to ethical consumerism, who wanted to create a high quality, revolutionary skincare range that would be a positive force in the beauty landscape. What differentiated Roddicks vision to other beauty giants was her desire to create the perfect harmony between quality, accessibility, environmental consciousness (starting out with refillable containers etc) and profit. That passion filtered through to employees - and the brand's ideology hasnt much changed along the years.

Helping disadvantaged communities is a brand priority and they have been sourcing their Community Fair Trade (CFT) shea butter from Tungteiya Womens Association in Northern Ghana since 1994. Where 640 women from 11 villages, handcraft shea butter using an 18-stage process of traditional techniques, successfully creating generational opportunities passed from mother to daughter. Their CFT handcrafted paper and gift packaging is also sustainably sourced from Kathmandu, Nepal.

A B Corp certified brand is amongst the 3,000 businesses worldwide to have the highest social and environmental standards for people and the planet. One focus is on using plant-based and recycled plastic (rather than oil-based plastics) and creating initiatives to aid consumers around the world to reuse, repurpose and recycle. In 2019, we reintroduced our pioneering refill scheme, a recycling programme and removed 21 tonnes of plastic from our gifts. says says Linda Campbell, Managing Director for the UK.

The ideals of The Body Shops founder had a direct impact on the direction of the brand. They havent shied away from supporting feminist movements, constantly raising the bar on ethical consciousness and fighting to empower girls and women across all demographics. The Body Shop have spent the last few years initiating and aligning with campaigns, most recently the Covid-19 response derived #IsolatedNotAlone campaign. With the objective of raising awareness on domestic abuse and providing potentially life-saving resources for survivors and bystanders at increased risk during lockdown measures." says Campbell.

If all this doesnt make you feel more passionate about the brand, we dont know what will. And that's before we even get the quality products at consumer friendly prices. But dont let the Body Shop name fool you though, as not only extensive bath and body sup, but skincare, haircare and vegan makeup.

If youre a lover of newness, you might want to investigate the latest drop, which includes Hemp Dry Body Oil, 14, and the Drops of Youth Bouncy Jelly Mist, 16. A gel-to-mist formula protect the skin from indoor and outdoor pollution as well as the effects of blue light from all the Zooming.

But the beauty giant is just as loved for its cult products, from the nourishing glow masks to their world famous body butters (which sell at a rate of one every three seconds). If you want to know what the hype is really about, here is a selection of the 10 bestselling products and why they deserve a spot in your bathroom cabinet.

See the rest here:
Here's Why The Body Shop Is A Cult Brand to Know Plus The Best-Sellers To Buy - GLAMOUR UK

Led by genetic counselor Jennifer Roggenbuck, MS, LGC, a one-year grant awarded by the ALS Association is funding Ohio States formal development of national clinical guidelines for ALS genetic testing that will be used by healthcare centers nationwide. We have cared for thousands of patients since opening our ALS/MND Clinic in the mid-1990s and have extensive experience with genetic testing, says Roggenbuck. We believe its extremely important to establish national testing standards, to ensure that all persons with ALS can benefit from genetic advances, and to fuel further research.

Genetic testing and counseling directly benefits our patients, explains clinic director Stephen J. Kolb, MD, PhD. Genetic characterization of our patients also opens the door to research opportunities. In addition to formal genetic counseling, our clinic has an ALS Clinical Research Coordinator who meets with every patient to explain our basic science and clinical trial opportunities and answer any related questions. Our patient partnerships are a key factor in the size and scope of our research program. Because Ohio State is now among the largest ALS research sites in the country, were regularly asked to participate in or lead high profile National Institutes of Health (NIH) and foundation studies.

A major focus of our program is to connect the individuals that we serve in clinic to the critical research efforts that are happening in laboratories here at Ohio State as well as those throughout the world. One example of this is the development of individualized models of disease, says Dr. Kolb. We and our collaborators are able to biopsy a persons skin cells and turn them into a type of stem cell that allow us to reproduce each patients exact ALS condition in the laboratory. We can then study the models to look for causes and develop therapies on a case-by-case basis.

The ALS/MND Multidisciplinary Clinic and Research Program is part of Ohio States Neurological Institute, with one of the largest neuromuscular centers in the country, so there is an established team of multidisciplinary experts to help each patient, even those with unusual or difficult symptoms. The ALS/MND program is led by Kolb, a physician-scientist, and in addition to the full-time research coordinator, he is joined by a clinical neurologist, genetic counselor, clinical nurse practitioner, social worker and nutritionist, as well as physical, occupational, respiratory and speech therapists. The Ohio State Department of Neurology is a member of NeuroNEXT: Network for Excellence in Neuroscience Clinical Trials and a contributing member to the Northeast ALS Consortium (NEALS).

Read feature stories

View post:
Ohio State establishing national standards for ALS genetic testing, research and patient care | Ohio State Medical Center - Wexner Medical Center -...

Global Plant Stem Cell Market 2020 by Company, Regions, Type and Application, Forecast to 2026

Plant stem cells are undifferentiated cells within the meristems of plants.Plantstem cellsserve as the origin of plant vitality as they maintain themselves and provide a steady supply ofprecursor cellsto form various tissues and organs in plants. Plant stem cells are characterized by two distinctive properties namely its ability to create differentiated celltypes and to self-renew such that the number of stem cells remain stable. The plant stem cell market focuses on this ability of plant cells and thus, processed extracts from the buds, roots and shoots are in high demand and are widely used for topical uses.

This report is an essential reference for those who look for detailed information on the Global Plant Stem Cell Market. The report covers data on global markets including historical and future trends for supply, market size, prices, trading, competition and value chain as well as Global major vendor information. In addition to the data part, the report also provides an overview of Plant Stem Cell market, including classification, application, manufacturing technology, industry chain analysis and the latest market dynamics.

Global Plant Stem Cell Market Research Reports provides information regarding market trends, competitive landscape, market analysis, cost structure, capacity, revenue, gross profit, business distribution and forecast 2024.

Plant Stem Cell Market was valued at xx million US$ in 2020 and will reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2020-2025.

The Global Plant Stem Cell market is highly competitive and consists of a number of major manufacturers like Oriflame Holding AG, MyChelle Dermaceuticals, LLC, Natura Therapeutics Inc, Aidan Products LLC, Mibelle Biochemistry, Phyto Science SDN BHD, and Renature Skin Care Inc.

Get PDF Brochure Of This Research Report @ https://www.coherentmarketinsights.com/insight/request-pdf/98

Scope of the Report:

The segmentation has been done on the basis of types, applications, technology, and users. Each segment has been further explained with the help of Table of Content, Tables and Figures. This breakdown of the market gives the readers an objective view of the global Plant Stem Cell market, which is essential to make sound investments. Both these assess the path the market is likely to take by factoring in strengths, weaknesses, opportunities, and threats.

This report also includes the overall and comprehensive study of the Plant Stem Cell market with all its aspects influencing the growth of the market. This report is an exhaustive quantitative analysis of the Plant Stem Cell industry and provides data for making strategies to increase the market growth and effectiveness.

The Global Plant Stem Cell market 2019 research provides a basic overview of the industry including definitions, classifications, applications and industry chain structure. The Global Plant Stem Cell market analysis is provided for the international markets including development trends, competitive landscape analysis, and key regions development status.

Development policies and plans are discussed as well as manufacturing processes and cost structures are also analyzed. This report also states import/export consumption, supply and demand Figures, cost, price, revenue and gross margins.

In addition to this, regional analysis is conducted to identify the leading region and calculate its share in the global Plant Stem Cell market. Various factors positively impacting the growth of the Plant Stem Cell market in the leading region are also discussed in the report. The global Plant Stem Cell market is also segmented on the basis of types, end users, geography and other segments.

On the basis of geography, the market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa.

Inquire Here Before Purchase of Research Report @ https://www.coherentmarketinsights.com/insight/talk-to-analyst/98

The major factors defined in this report are:

The study objectives of this report are:

To study and analyze the global Plant Stem Cell consumption (value & volume) by key regions/countries, product type and application, history data from 2014 to 2018, and forecast to 2024.

To understand the structure of Plant Stem Cell market by identifying its various subsegments.

Focuses on the key global Plant Stem Cell manufacturers, to define, describe and analyze the sales volume, value, market share, market competition landscape, SWOT analysis and development plans in next few years.

To analyze the Plant Stem Cell with respect to individual growth trends, future prospects, and their contribution to the total market.

To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).

To project the consumption of Plant Stem Cell submarkets, with respect to key regions (along with their respective key countries).

To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

To strategically profile the key players and comprehensively analyze their growth strategies.

LIMITED TIME OFFER Hurry Up!

Get Discount For Buyers UPTO 30% OFF On Any Research Report

Apply Promo Code CMIFIRST1000 And Get Instant Discount Of USD 1000

Ask For Discount Before Purchasing This Business Report @ https://www.coherentmarketinsights.com/insight/request-discount/98

Table of Content:

Chapter One: Industry Overview of Plant Stem Cell

Chapter Two: Manufacturing Cost Structure Analysis

Chapter Three: Development and Manufacturing Plants Analysis of Plant Stem Cell

Chapter Four: Key Figures of Major Manufacturers

Chapter Five: Plant Stem Cell Regional Market Analysis

Chapter Six: Plant Stem Cell Segment Market Analysis (by Type)

Chapter Seven: Plant Stem Cell Segment Market Analysis (by Application)

Chapter Eight: Plant Stem Cell Major Manufacturers Analysis

Chapter Nine: Development Trend of Analysis of Plant Stem Cell Market

Chapter Ten: Marketing Channel

Chapter Eleven: Conclusion

Continued here:
Plant Stem Cell Market- Growth Opportunities by Manufacturers, Regions, Type and Application; Trends Forecast to 2026 | Coherent Market Insights - The...

Regenerative Medicine Market Major Players:

Players active in the global regenerative medicine market include Osiris Therapeutics, Cook Biotech, Organogenesis, Baxter International, Inc., Stryker and RTI surgical, LifeSciences, CryoLife, Advanced Cell Technology, Sanofi, BioMimetic Therapeutics, Medtronic, StemCellsInc, and LifeCell Kinetic Concepts, among others.

ALSO READ :https://sapanas.tumblr.com/post/631130245458739200/regenerative-medicine-market-competitive-analysis

Regenerative Medicine Market Outlook

Global regenerative medicine market is growing continually, witnessing a massive uptake. Market growth primarily attributes to the increasing advancement in healthcare technology and the growing prevalence of chronic diseases. Besides, improvements in the field of regenerative medicine and stem cell technology drive the growth of the market excellently.

Moreover, the rising uptake of therapeutics such as stem cell biology, cellular therapy, tissue engineering in applications, including cord blood, oncology, urology, orthopedics, neurology, dermatology, and others accelerate the market growth. According to Market Research Future (MRFR), the global regenerative medicine market is poised to grow at 25.4% CAGR throughout the forecast period (2016 2022).

ALSO READ :https://yarabook.com/read-blog/138540

Additionally, the rising uptake of stem cell & tissue engineering processes in the treatment of health issues ranging from orthopedics, musculoskeletal & spine, dental, and skin/integumentary to cancer, neurology, and cardiology substantiate the market growth. Furthermore, the increasing rate of road accidents, injuries, and trauma cases drive the market exponentially, driving the demand for transplants & surgical reconstruction procedures.

On the other hand, factors such as the lack of awareness, skilled professionals, and stringent regulatory policies are projected to act as significant impeders for market growth. Nevertheless, funding support for the development of regenerative medicines would support the growth of the market throughout the predicted period. Also, widening application areas of regenerative medicines in the field of stem cell reconstructive and skin grafting would increase the market growth.

Global Regenerative Medicine Market Segments

The analysis is segmented into four dynamics;

By Material: Synthetic Materials, Genetically Engineered Materials, Pharmaceuticals, and others.

By Therapy: Stem Cell Biology, Cellular Therapy, Tissue Engineering, and others.

By Application: Cord Blood, Oncology, Urology, Orthopedics, Neurology, Dermatology, and others.

ALSO READ :http://www.marketwatch.com/press-release/fram-market-2021-industrytrends-opportunities-market-volume-competitive-landscape-possible-challenges-and-forecast-to-2025-2021-01-06

By Regions: Americas, Europe, Asia Pacific, Middle East & Africa, and Rest-of-the-World.

Regenerative Medicine Market Regional Analysis

North America is projected to continue dominating the globalregenerative medicine marketthroughout the forecast period. In 2015, North America accounted for more than 44% of the overall market share. This huge market growth attributes to the presence of a large number of major players and pharma & biotechnology companies. Moreover, huge investments made by public & private organizations drive the regenerative medicine industry in the region.

Besides, the rising prevalence of chronic diseases and orthopedic issues and increasing clinical trials to evaluate the therapeutic potential of products foster regional market growth. Also, the well-spread awareness towards the therapeutic potency of regenerative medicines impacts the market growth positively. The North American regenerative medicine market is expected to grow at a robust CAGR of 22.3% over the review period.

Europe stands second in the global regenerative medicine market. Factors such as the increasing per capita healthcare expenses and penetration of healthcare sectors in the region boost the market growth. Additionally, the rising government support and R&D funding in the life science developments substantiate the regional market growth. Markets in the UK, Germany, and France, contribute to the regional market majorly. The European regenerative medicine market is estimated to grow at 22.5% CAGR during the assessment period.

ALSO READ :http://www.marketwatch.com/press-release/m2m-communication-market-demand-to-rise-amid-industrial-automation-industry-analysis-with-business-trends-covid19-outbreak-competitor-strategyforecast-to-2023-2021-01-05

The Asia Pacific regenerative medicine market has emerged as a rapidly growing market. Factors such as the large advances in biotechnology and increasing government support for R&D are fostering the growth of the regional market. Regenerative medicine markets in highly populated countries such as China, India, and Japan support the regional market growth excellently, heading with huge technological advances. The APAC Regenerative Medicine market is predicted to demonstrate huge growth potential.

Global Regenerative Medicine Market Competitive Analysis

The well-established regenerative medicine market appears to be highly competitive with the presence of several notable players. To gain a larger competitive advantage, market players incorporate strategic initiatives such as mergers & acquisitions, expansions, and product/technology launch. Also, they make substantial investments to drive R&D to develop their capabilities and to expand their global footprints. Simultaneously, R&D funding programs initiated by the governments to enhance regenerative medicine capabilities are offering high growth potential. This is further going to attract several new entrants to the market and intensify the market competition further.

Regenerative Medicine Industry/Innovations/Related News:

March 15, 2020 - Research team at the University of Sheffield published their study on stem cell mutations that could improve regenerative medicine in the magazine Stem Cell Reports. Their study gives new insights into the cause of mutations in pluripotent stem cells and potential ways of stopping these mutations from occurring. It also suggests ways to reduce the likelihood of variations occurring in these cells when cultured. There is considerable interest in using Pluripotent stem cells to produce cells that can replace diseased or damaged tissues in applications referred to as regenerative medicine.

ALSO READ :http://www.marketwatch.com/press-release/waste-to-energy-market-share-size-key-players-regional-study-and-forecast-2024-2020-12-30

https://neighborwebsj.com/

Read the original post:
Global Regenerative Medicine Market Insights, Overview, Analysis and Forecast 2022 NeighborWebSJ - NeighborWebSJ

Women with attention-deficit/hyperactivity disorder (ADHD) may be more vulnerable to hormone-related mood disorders such as premenstrual dysphoric disorder (PMDD), postpartum depression (PPD), and climacteric mood symptoms during their lifespan, researchers found in a study that was recently published in the Journal of Psychiatric Research.

The study included 209 adult female patients with ADHD (mean age of 34.5 years, standard deviation (SD) of 11.5 years) who were in care in April and May 2016 at the PsyQ outpatient clinic for Adult ADHD in The Hague, the Netherlands.

Of the participants, 174 were of reproductive age, 35 were peri-or-postmenopausal and 70 had irregular menstrual cycles. Of the 85 participants who had at least 1 biological child, 53 (62.4%) reported having complications antepartum, peripartum and/or postpartum after their first childbirth.

The researchers assessed the patients using the Diagnostic Interview for ADHD in adults 2.0 based on DSM-IV criteria, the Neuropsychiatric Interview Plus (the M.I.N.I. Plus), the Edinburgh Postnatal Depression Scale (EPDS), the Greene Climacteric Scale (GCS) and the Munich Chronotype Questionnaire (MCTQ).

More women with ADHD and PMDD used contraceptives (50.6%) than those who did not have PMDD (68.1%, 2 (1) = 5.82; P =.016, odds ratio (OR) = 2.09). PMDD symptoms were associated with the use of antidepressants (t = 1.991, P =.048), contraceptives (t = 2.515, P =.013), complications during pregnancy (F = 5.385, P =.008) and a mood disorder in remission (t = 2.500, P =.013). Adjusting for covariates and correcting for age and education level, use of contraceptives was associated with lower PMDD symptoms, and using antidepressants was associated with higher PMDD symptoms.

The prevalence of PPD indications (49 of the 85 who had at least 1 biological child) after the first childbirth was higher among the women included in the study than groups included in 2 systemic reviews: 19.6% among low-to middle-income countries and 14.5% in high-income countries. PMDD symptoms were significantly higher in the PPD-group compared to the no-PPD-group, with a medium effect size, (M = 7.38, SD = 3.28 vs. M = 5.53, SD = 4.07; t (81) = 2.30, P =.024, d = 0.50). The PPD-group used significantly more antidepressants (49% of the patients) than the no-PPD-group (25%, 2 = 6.330; P =.010).

The researchers found significant differences on GCS subscores for depression between the 11 women with PMDD and the 14 without PMDD (F (1) = 5.105, P =.030) and sexual dysfunction (F (1) = 5.191, P =.029) as well as a significant correlation between more PMDD symptoms and higher total GCS (r = 0.511, n = 38, P =.001) and the subscores psychosocial (r = 0.441, n = 38, P =.006), anxiety (r = 0.381, n = 38, P =.020), depression (r = 0.0418, n = 38, P =.010) and somatic (r = 0.425, n = 38, P =.009) complaints. The PPD group (n = 18) showed significantly higher GCS scores (vs. no PPD, n = 8) on the total score (F = 7.18 (1), P =.013), the subscores psychosocial (F = 6.01 (1), P =.021), anxiety (F = 5.84 (1), P =.023), depression (F = 4.51 (1), P =.043), vasomotor (F = 7.03 (1), P =.013) and sexual dysfunction (F = 4.56 (1), P =.043).

Limitations of the study include possible recall bias and the inability to find significant association between a broad spectrum of psychiatric disorders and PMDD.

Reference

Dorani F, Bijlenga D, Beekman ATF, van Someren EJW, Kooij JJS. Prevalence of hormone-related mood disorder symptoms in women with ADHD. J Psychiatr Res. Published online December 3, 2020. doi:10.1016/j.jpsychires.2020.12.005

Link:
Women With ADHD May Have More Severe Symptoms of Premenstrual Dysphoric Disorder, Postpartum Depression, and Menopause - Psychiatry Advisor

Lets face it, guys: getting old isnt easy. Whether youre just entering your 40s or youre in the middle of your retirement years, you know that your body doesnt look or function the same way it did 5, 10, 20, or even 30 years ago. However, the first step toward slowing the aging process is knowing what signs to look out for. Once you know what age looks like, you can start implementing methods to combat physical signs of aging at their source. So, lets take a closer look at the four signs of aging in men that you should be aware of!

Erectile dysfunction is one of the most common medical issues in men aged 40 or over. While some men feel uncomfortable talking about this problem, theres no shame in it. It is extremely common and is in no way a reflection of your masculinity. As men age, their blood vessels shrink, their hearts weaken, and their circulation slows. As a result, it can become harder to get and maintain an erection. While there are plenty of short-term fixes available on the market, you can also try out GAINSWave therapy through the ThriveMD clinic. In fact, GAINSWave therapy is one of the best ways to improve your sex life for the long-term!

The jury is still out on whether or not the dad bod is a good look for men, but either way, its a common sign that youre getting older. Testosterone is the hormone in your body that is responsible for building muscle mass. As you age, your levels of testosterone begin to taper off and eventually decline. This leads to decreased muscle production throughout the body, including the abdomen. When your abs become weaker, a belly will form. However, regular exercise and even hormone therapy can easily reverse or prevent this issue.

Unfortunately, theres only so much you can do about your genetics. Some men begin balding in their 20s, while others keep a full head of hair well into their 80s, 90s, and beyond! It all depends on your genetics. However, the vast majority of men will start to experience some degree of hair loss when they reach 40. As you age, your hairline will likely continue to recede. However, there are plenty of products that can slow or even reverse this process. If you dont mind taking the artificial route, hair plugs are a great way to cover up bald patches as well.

Though age spots can occur in both men and women, they are a little more common in men. These spots often appear as dark brown or tan spots on the skin. Age spots can appear just about anywhere, though they are most common on the hands, arms, face, neck, and back. Sometimes known as liver spots, age spots are often the result of excessive sun exposure over a long period of time. Thus, you can reduce the risk of getting age spots by limiting your sun exposure and wearing protection against the sun (like sunscreen).

Photo: Shutterstock

Link:
4 Signs of Aging In Men That You Should Be Aware Of - The Good Men Project

DEAR MAYO CLINIC: My mom was diagnosed with breast cancer. During her care, she was found to have a BRCA2 mutation. Her doctor suggested that my brothers and I get tested for this mutation, too. I am a 26-year-old woman, and I am not sure what this means for me and my risk of cancer.

ANSWER: Having a loved one with a breast cancer diagnosis can be scary. It also can become confusing when you start to hear about genetic mutations. The good news is that the information can help guide your family regarding screening and future cancer risk.

BRCA2 is a genetic abnormality that can be passed down from a parent to children. It is autosomal dominant, which means there is a 50% chance that each of your moms biological children could have the mutation. Being positive for the mutation would mean that you or your brothers may be at increased risk of developing certain cancers, compared to the general population.

In addition to breast cancer, these cancers are also known to be associated with BRCA2: ovarian cancer, melanoma, prostate cancer and pancreatic cancer.

To understand your risk, you would want to meet with a genetic counselor who can help you understand the implications of undergoing genetic testing and whether this is something you want to do. Typically, genetic testing is performed using a blood or saliva sample. The counselor would review the results with you and, if you are positive, recommend next steps to learn more about personalized screening and specific risk reduction options.

Generally speaking, it is recommended that women who have a BRCA2 mutation begin monthly breast self-examinations, beginning at 18. Clinical breast examinations are recommended every six months, beginning at 25, or before if there is an earlier breast cancer in the family. Annual breast MRIs should begin at 25. Tomosynthesis mammograms are recommended annually, beginning at 30. They are usually alternated with breast MRIs every six months. Based on risk and family history, some woman may choose to undergo a preventive mastectomy to remove their breast tissue and hopefully decrease their risk of developing breast cancer.

There is no screening test for ovarian cancer. However, women can have transvaginal ultrasounds and a blood test called CA 125 every six to 12 months, beginning at ages 30-35, while their ovaries are still in place.

If desired, women can undergo surgery to remove their ovaries and fallopian tubes once they are done having children. Ideally, this would occur between the ages of 40-45. As this surgery results in women going through menopause, some women may be started on hormone therapy until ages 50-51 to alleviate menopausal symptoms and offset some long-term risks associated with early menopause.

Research has shown that many ovarian cancers begin in the fallopian tubes. With this knowledge, women have recently been having surgery to remove their fallopian tubes and delay surgery to remove their ovaries for a few years though the recommended age for a woman to have her ovaries removed is still 40-45 in a BRCA2 mutation carrier. The benefit of removing just the fallopian tubes is that this allows women to preserve their natural hormonal function longer. The safety of this strategy is being studied, and this type of surgery is being performed as part of clinical trials.

Women who undergo surgery to remove their ovaries before menopause have a 50% reduction in their risk of developing breast cancer. In addition to surgeries, there are medications that can be given to help decrease the risk of developing breast and ovarian cancers. Selective Estrogen Receptor Modulators (SERMS) and Aromatase Inhibitors (AIs) are types of medications that can reduce the risk of developing breast cancer. Oral contraceptives can decrease the risk of developing ovarian cancer by 50%.

Since the BRCA2 mutation can be passed down to offspring, understanding your status and that of a future partner is important, as there is a genetic condition called Fanconi anemia that can occur if both the male and female partners have a BRCA2 mutation.

Thus, for men and women who test positive for BRCA2 and have not yet had biological children, it may be worthwhile to meet with a specialist in reproductive endocrinology and infertility to discuss options.

There are no standard screening guidelines for pancreatic cancer or melanoma. Based on your situation, a consultation with a pancreatic specialist may be worthwhile to discuss whether to pursue MRI or endoscopic ultrasound. Likewise, a referral to a dermatologist can be made to initiate skin cancer screenings.

Understandably, you may be nervous about your risk for cancer, given your mothers diagnosis. However, you are young, and you should not feel rushed to make any decisions regarding genetic testing. If you choose to undergo testing and are found to have a BRCA2 mutation, your health care providers will give you the information that you need so that you can begin to think about what makes sense for your life and your priorities.

Casey Swanson, physician assistant, Gynecologic Surgery, Mayo Clinic, Rochester, Minnesota

As an Amazon Associate I earn from qualifying purchases.

Originally posted here:
Genetic abnormalities and cancer risk | Mind and Body | nny360.com - NNY360

Transcranial magnetic stimulation (TMS) is a type of brain stimulation therapy.

Its a noninvasive treatment that uses electromagnetic pulses to stimulate nerve cells, which may improve symptoms of neurological or mental health disorders.

TMS is mainly used to treat depression. Its had success helping people who dont respond to antidepressant medication and psychotherapy. In fact, in 2008 the Food and Drug Administration (FDA) approved TMS for this purpose.

Theres also some evidence that TMS may help other disorders, like anxiety and Parkinsons disease.

Since TMS uses repetitive electrical impulses, its sometimes called repetitive transcranial magnetic stimulation (rTMS). The terms are often used interchangeably.

If youre curious about the benefits and side effects of TMS, read on.

The therapy is done by a TMS technician or TMS physician. Its an outpatient procedure, so it may be done in a medical clinic. If its done in a hospital, you wont need to stay overnight.

Before the procedure, youll need to remove items that are sensitive to magnets, like jewelry.

Heres what you can expect during TMS:

Youll need to repeat the procedure 5 days a week, for about 4 to 6 weeks. The exact length of your treatment depends on your response and specific condition.

There are many possible benefits of TMS therapy. Researchers are still studying the procedure, but it may help the following conditions:

TMS is primarily used to treat major depressive disorder (MDD), sometimes simply called depression.

Its generally recommended for those who havent found relief from medication and psychotherapy. This is called treatment-resistant depression. Approximately 30 percent of people with depression dont respond to these treatments.

According to 2015 research, depression is linked to reduced activity in the prefrontal cortex. This part of the brain is involved with depression symptoms, like low energy levels and appetite changes.

TMS may help by stimulating nerve cells and increasing activity in this area.

TMS may improve symptoms of obsessive-compulsive disorder (OCD).

The FDA approved TMS for OCD in 2018. As with depression, TMS is recommended if a person with OCD hasnt responded to medication and psychotherapy.

According to one study, people with OCD often have increased activity between the prefrontal cortex and striatum. This hyperconnectivity is associated with severe OCD symptoms.

TMS can be used to inhibit the activity in this part of the brain, thus reducing OCD symptoms.

As TMS treats psychological disorders like depression and OCD, it may also ease anxiety. Thats because these conditions often cause anxiety symptoms.

TMS could also be beneficial for generalized anxiety disorder (GAD).

In anxiety, theres often increased nerve cell activity in the prefrontal cortex. TMS may reduce the activity in this region, according to a 2019 study.

According to a 2019 review, TMS showed effectiveness for post-traumatic stress disorder (PTSD). As mentioned, TMS can target the prefrontal cortex, which regulates how you process fear and worry.

A 2018 trial found that TMS alongside cognitive processing therapy was effective for PTSD. The therapeutic effect of this combination lasted for 6 months.

Theres some evidence that TMS may help stroke rehabilitation.

A stroke happens when blood flow to the brain is blocked or reduced, causing brain cells to die. This can result in long-term loss of muscle movement.

According to research, using TMS after a stroke could promote motor recovery. The idea is that the magnetic impulses can alter the activity of the motor cortex, the part of the brain that controls voluntary movement.

A 2017 article also shares that TMS may improve dysphagia, or difficulty swallowing, by stimulating the motor cortex. They add that dysphagia affects 50 percent of people who have experienced a stroke.

Schizophrenia is a chronic, and often severe, psychiatric disorder.

A main symptom of the condition is auditory hallucinations, which affect 75 percent of people with schizophrenia.

According to a 2019 review, targeting the temporoparietal cortex could be beneficial for auditory hallucinations. This part of the brain, which is involved in language, is typically overactive in schizophrenia.

Parkinsons disease is a neurological disorder. It causes motor dysfunction, including tremors, balance issues, and freezing of gait. Freezing of gait occurs when you feel frozen and cant move while walking.

A 2020 study found that TMS may improve freezing of gait. According to the researchers, TMS normalized the connections between parts of the brain involved in gait freezing.

TMS might have benefits for Alzheimers disease, a form of dementia. This disorder causes progressive memory loss and cognitive decline.

According to newer research, its thought that TMS could help Alzheimers disease by altering the neural connections involved in memory and learning. However, more research is necessary to understand how TMS can manage Alzheimers disease.

TMS could potentially improve chronic pain conditions, such as fibromyalgia. A 2017 analysis shares that it may help by stimulating the motor cortex and controlling neurotransmitters involved in pain.

Its worth noting that depression and chronic pain often occur together. Depression can worsen chronic pain, so TMS may help by treating depression symptoms.

Nicotine releases dopamine, also called the happy hormone. It sends signals to the reward system of your brain, including the prefrontal cortex, resulting in nicotine cravings and addiction.

According to a 2013 study, TMS could help reduce nicotine cravings by targeting the prefrontal cortex.

The researchers think that TMS promotes the release of dopamine, which reduces the need for nicotine.

Multiple sclerosis (MS) is a chronic autoimmune disorder that affects the nervous system. It commonly causes spasticity, or muscle tightness that makes it difficult to move.

In a 2019 study, researchers used TMS on the motor cortex of people with MS. The treatment, combined with physical therapy, was found to decrease spasticity.

To date, TMS therapy has mostly been studied as a treatment for depression.

The success rate of TMS for depression is promising. Response rates for depression are between 30 and 64 percent.

More research is needed to understand the success rate for other medical conditions.

If you have depression, a doctor will likely recommend antidepressants and psychotherapy before TMS.

However, you may be a good candidate for TMS if you:

If youre young, TMS might be an ideal choice. Thats because younger people are more prone to developing adverse side effects from antidepressants.

TMS is considered safe, but its not for everyone.

You should avoid this treatment if you have metal in your head, such as:

The magnetic fields in TMS can make these implants heat up or move, which can cause serious injuries.

Its OK to get the treatment if you have braces or dental fillings.

You may also need to avoid TMS if you:

TMS side effects are uncommon. If complications do occur, they may include:

Symptoms like headaches and lightheadedness usually go away after several treatments.

Theres also the risk of seizures, but this side effect is rare. Theres a 0.1 percent risk of developing seizures during a course of TMS therapy.

One course of TMS can cost between $6,000 to $12,000 out of pocket.

Your health insurance provider might offer coverage, but this depends on your medical history. You may be required to try at least four antidepressants before receiving TMS coverage.

Alternatively, they might provide coverage if you experience negative reactions when using antidepressants.

If antidepressants and psychotherapy dont work for you, Medicare will cover TMS therapy.

Since youre expected to get treatment 5 days a week for multiple weeks, you may have to miss a few hours of work each day. This depends on your schedule, the location of the clinic, and the time of your appointments.

One session can take anywhere from 30 to 60 minutes, so you may be able to do the treatment before or after work.

TMS targets the activity of nerve cells in your brain, which may alleviate depression symptoms. It could also have benefit for disorders like OCD, anxiety, and PTSD as well.

The procedure may even improve motor dysfunction, making it potentially helpful for Parkinsons disease, multiple sclerosis, or stroke rehabilitation.

If youre interested in TMS, talk with a doctor. You may be a good candidate if youre young, have a low risk of seizures, and havent felt relief from antidepressants.

Link:
TMS Therapy: What It Treats, Benefits, Side Effects, and Costs - Healthline

breathe ilo, OCON Healthcare and Eli are three femtech startups innovating in the fertility and ... [+] contraception space

Its not a secret that finally, after years of being overlooked, womens health is having its moment. According to Frost & Sullivans report, the femtech (female technology) market revenue is expected to reach $1.1 billion by 2024, growing at a compound annual growth rate (CAGR) of 12.9%. The report states that, through solutions targeting early diagnosis and leveraging connected healthcare services, these technologies can reduce healthcare costs, decreasing the overall cost burden of a country while elevating healthcare standards and quality of life for women. But it took a long time for female healthcare to be where it is today.

Ever since the FDA (The United States Food and Drug Administration) in 1977 issued a guideline banning most women of childbearing potential from participating in clinical research studies (since certain drugs at that time were causing serious birth defects), women werent included (at least not enough) in medical research. In 1985, new guidelines were issued to encourage more inclusion of women in studies. However, even that wasnt enough to close the gender gap in medical research - analyses found that women were still seriously underrepresented in important studies on common diseases such as heart disease. Finally, in 1993, the FDA issued a new guideline which was followed by Congress writing the NIH inclusion policy into Federal law through a section in the NIH Revitalization Act of 1993 titled Women and Minorities as Subjects in Clinical Research.

Fast forward to today, womens health as a category has gone beyond just healthcare, is hugely impacted by the use of technology, and is all but a niche - it affects more than just females - fertility, for example, is not just a womens issue, despite the misconception that (in)fertility is still a largely female problem (40-50% of all fertility problems are due to the male factor).

The femtech industry has generated just over $376 million in venture capital across 57 deals in 2020 and some of the largest exits in recent years include femtech companies - Progynys $130 million IPO in 2019 and Bayers acquisition of KaNDy Therapeutics in 2020 for $425 million. $688.8 million has been invested in digital health companies targeting fertility and pregnancy/motherhood through H1 2020, which represents 65% of all femtech funding. The potential of it is massive - female health is not just female health, it affects men, children, and whole families as women are primary caregivers more often than not. Female health is a public health issue and should be treated as a priority.

Below are three startups leading the way in innovation in this space, proving that no area within the femtech space is saturated with innovative companies and that there is still so much growth potential in this market.

Breathe ilo is the worlds first fertility tracker that uses breath analysis to identify a womans ovulation pattern and fertile window in a way that is easy and comfortable. Its technology is based on measuring the PCO2 parameter, which means the partial pressure within the carbon dioxide. Simply said, the device measures a decrease in womens breath before ovulation. What most women dont know (I certainly didnt!) is that they have a type of hyperventilation 4-5 days prior to ovulation. Through consistent daily use, the breath analysis tracker enables women to understand their body and cycle phases better. Additionally, the breathe ilo app, which is compatible with iOS and Android, features a calendar that displays a clear overview of fertile days and a cycle diary to learn more about individual cycle patterns and also enables users to document further cycle symptoms like breast tenderness, PMS, cervical mucus, or headaches to help prepare women for their next cycle.

breathe ilo is the worlds first fertility tracker that uses breath analysis to identify a womans ... [+] ovulation pattern and fertile window

The technology behind our device means women no longer need to track their cycles by urinating on a stick or by measuring their temperature early in the morning. All they need to do is simply breathe into the device which will display the result in just 60 seconds on the mobile phone, with no consumables or maintenance needed. Another positive thing is that you can use it at any time of the day, which makes it accessible for every woman, even those who have no daily routine, Lisa Krapinger, CMO of Vienna-based Carbomed Medical Solutions, the company behind breathe ilo, shares with me in an interview.

The idea for this type of product came from Prof. Dr. Ludwig Wildt from the University Clinic Innsbruck, who dedicated decades of research on the relationship between the female cycle and CO2. Something that started as a side project for the breathe ilo co-founder and CEO Bastian Rther. Investing in combined hardware and software products needs brave investors. First of all, the funds needed until profitability are usually higher than in pure software products. Furthermore, the skill set of the organization needs to be much broader and the organization will be much more complex because of managing all the supply-chain complexity. Our latest round was a Pre-Series A round of $3.6 million, led by the AWS Grnderfonds, one of the largest Austrian Venture Capitalists, with the participation of our existing shareholders, he shares with me.

We want to continuously improve breathe ilo and make it truly accessible to every woman. Unfortunately, there are a variety of different diseases such as PCOS, which havent been well researched. Therefore, we are trying to research different areas to try and have a holistic view of women's health. We really want to help all women to fulfill their desire to have children, even if there are physical impairments. However, this requires very expensive, time-consuming studies. Furthermore, in the future, we would also like to provide breathe ilo for natural contraception and further breath analysis applications. We have achieved to make breath analysis tremendously affordable and can really see a mass market for it, so I think we are on a good track to revolutionize cycle tracking, concludes Krapinger.

Among the 1.9 billion women of reproductive age (15-49 years) living in the world in 2019, 1.1 billion have a need for family planning, that is, they are either current users of contraceptives - 842 million use modern methods of contraception. Approximately 160 million women (17%) use IUDs (intrauterine devices) globally - varying in market share between countries, IUDs are the most widely used long-term, reversible contraceptive method in the world. Yet there has been no OCON Healthcare innovation in the IUD space since the 1990s with current devices using a deficient delivery platform invented in 1970.

OCON Healthcare, an Israel-based company is here to change that. Its first product is the IUB Ballerine - the first and only 3D intrauterine device shaped for women's anatomy and is a long term, reversible, hormone-free contraceptive method replacing the 2D traditional T-shaped IUDs. But contraception is not the only reason for OCONs innovation in this space. On top of the IUB Ballerine, any drug or substance that can be introduced into the uterus can be potentially put on the flexible, smart memory shape IUB (Intra Uterine Ball) frame to be non-invasively delivered to the uterus and treat various medical conditions, replacing invasive procedures.

OCON's IUB Ballerine is the first and only 3D intrauterine device shaped for women's anatomy and ... [+] is a long term, reversible, hormone-free contraceptive method replacing the 2D traditional T-shaped IUDs

Abnormal Uterine Bleeding (AUB) affects up to 25% of women globally with a $1B annual addressable market, more than 70% of women develop uterine fibroids by the age of 50, which is 9 million women in the U.S. alone, and hormone replacement therapy, of which the market size was valued at $21.8 billion in 2019, are all areas we are looking into and in which we are developing innovative solutions to cater to women who need them, Keren Leshem, CEO of OCON Healthcare, shares with me.

Leshem joined the company in September 2019, and very quickly put the company on the trajectory of growth. The company now has 100,000-plus women who had the IUB Ballerine inserted by their doctor and this innovative contraceptive is currently sold in 30 markets in Europe, Middle East, Africa, and Latin America. Its a company led by women for women, as Leshem says, with 85% of its team being women now, including their newly appointed Chairwoman, California based life science VC leader Dr. Anula Jayasuriya.

In 2020 OCON raised a total of $4.5 million in funding from both internal and external investors as well as non-dilutive government funding for their R&D projects. To date, the company has raised almost $20 million and our investors include Pontifax VC, Docor VC, Rhia Ventures, Merchavia Investments, and other angel groups. This year, for the first time in my life, Ive witnessed the fundraising process being done completely online. It's weird to have such a connection and find amazing support when we haven't met personally with the teams in the U.S. that placed their confidence and money on us, adds Leshem. The company is now actively raising a Series B round to bring their innovative platform to the USA, so investors, what are you waiting for?

Eli is a Canada-based startup developing a hormone tracking product designed to be used at home. From the users perspective, there are three simple steps. You take a saliva sample with the cartridge, you insert it in the small portable device that captures your daily hormone fluctuations, and shortly after, the app provides powerful information tailored to you. This information includes your hormonal profile and precise fertile days. With this data, customers can achieve different goals, including avoiding pregnancy naturally or conceiving a baby. The product will initially be available only for people trying to conceive, while Elis team complete the clinical and regulatory work for the contraception use-case.

Fertility is a booming market, with 1 in 7 couples who experience infertility. This number is still growing because we are waiting longer than any generation ever to have children, and fertility declines with age, but the effects of age are much greater in women compared to men. In their 30s, women are about half as fertile as they are in their early 20s, and womans chance of conception declines significantly after age 35. Male fertility also declines with age, but more gradually.

So what makes Elis product so unique? We first asked ourselves what the ideal solution would look like and asked the same question to hundreds of women and dozens of physicians. It was clear that we had to make no compromise on ensuring its effective and delightful to use, in addition to being hormone-free and non-invasive. That process led us to build technology from the ground up because no existing product met all of those criteria. The technology's ability to measure multiple hormones (instead of proxy variables like temperature or cervical fluid) and to have saliva as an input (instead of urine or blood) is some of the elements that make our product unique. Because we built the technology by keeping contraception in mind, it was critical for the product to be reliable and simple to integrate into a routine that you keep for a long time. Measuring hormones can give the effect we were looking for, and using saliva is the foundation for delivering the best long-term experience, explains Marina Pavlovic Rivas, co-founder, and CEO of Eli.

Eli is developing a hormone tracking product designed to be used at home using woman's saliva

But its not only about fertility, for that matter. After using hormonal contraception for years, many women just want to stop at some point, not for the sake of getting pregnant, but because of many other reasons. Although hormonal contraception is one of the most significant advances of the last century for women and all of society, up to 51% of women using hormonal birth control report unwanted side effects. The problem is that when you want to avoid hormones and invasive devices, youre left with very few effective options. That means you either continue to use a method you no longer want to use or opt for a less effective option, and both cases should be unacceptable. Women's contraceptive needs have evolved, but innovations to meet those needs haven't followed. On top of that, hormones are at the root of so many transitions and conditions women experience, and yet they are still a black box for most of us, Rivas adds.

Since the company's creation a little over a year ago, Eli has raised over $2 million. This includes a $1.5 million seed round that the company closed in December 2020. Vectr Ventures and 2048 Ventures co-led the round with the participation of Real Ventures, Techstars, Panache Ventures, Ramen Ventures, MEDTEQ+, and serial entrepreneur Steven Arless, who also joined the board. Before this round, Eli received around $700,000 in external funding. Most of it came from equity-free sources, such as government programs rewarding companies developing breakthrough technologies. It also includes an initial investment startup received in fall 2019 a few weeks after starting the company from Techstars and Real Ventures, via Techstars Montral AI. Both investors subsequently invested in Eli's seed round.

No one could have predicted the challenges of raising during a pandemic. We were aware that some stats were not favorable even before that new context. Only 90 Latina founders have ever raised $1-plus million, and less than 3% of all VC funded companies have a woman CEO. However, it turns out that the pandemic reduced VC funding for female founders even more. With a 48% drop in funding to female founders from Q2 to Q3 2020, it hit its lowest since 2017. We were operating for a few months only when the global health crisis hit. It certainly added a layer of complexity at first. As a deep tech company with a hardware portion, we couldn't become entirely remote because we still needed to work with specialized equipment and controlled testing environments in the lab. We now have been running for longer under the global pandemic than in the pre-COVID era. It turns out that the current context holds several opportunities that accelerated our operations and amplified the need for our product, concludes Pavlovic Rivas.

Read the rest here:
These 3 Women Are Shaping The Future Of Womens Health By Bringing Next Generation Of FemTech Products To The Market - Forbes

Indiana State Sen. J.D. Ford introduced Senate bill 32 last week calling for a ban on the use of conversion therapy for minors. Ford is recognized as Indianas first openly gay state legislator and spoke of the bill as a lifesaving issue. However, the bill will most likely face stiff opposition from the Republican supermajority in the Statehouse.

Conversion therapy is used as an umbrella term to describe practices that involve an attempt to change a persons sexual orientation or gender identity through psychological, spiritual or physical intervention. A therapist can recommend an unsubstantiated medication plan consisting of antipsychotics or hormone injections as a psychological treatment.

[Related: OPINION: Indianas first openly gay senator is right. A vote for Mike Pence is one for homophobia.]

Conversion therapy perpetuates harmful stereotypes by suggesting people can be cured of their deviance. The vile practice treats homosexuality and gender identity as an illness and invalidates any reality other than one consisting purely of heterosexuality and cisnormativity.

Religious leaders might insist homosexuality is a sin, therefore repentance is the answer. Health professionals may perform aversive treatments in the form of electroconvulsive therapy to punish an individual for indulging in thoughts which deviate from the arbitrarily defined sexual norm.

An estimated 700,000 LGBTQ adults in the United States have experienced some form of conversion therapy, and half of which received it while they were adolescents.

Conversion therapy is torture.

Nevertheless, it remains legal in a majority of states, including Indiana.

Indiana lawmakers proposed a ban on conversion therapy in 2019 but it never appeared before the entire chamber for a vote. The measure quickly died in committee.

Although Indianas reconsideration of a conversion therapy ban is a step towards progress, the bill is unlikely to pass. Republicans hold a nearly identical supermajority in the Indiana General Assembly as they did two years ago when similar legislation failed.

If the ban passes, however, legislators should acknowledge the long-term implications of conversion therapy and provide LGBTQ communities with further resources and support.

The American Psychological Association and the World Psychiatric Association are just a few of the many health organizations that denounce the use of conversion therapy and reject its asserted scientific premise.

[Related: IU students conduct LGBTQIA+ health care needs survey to establish free student-run clinic]

The trauma that forced conversion creates for young people in particular is alarming, and the inequality it legitimizes is damaging to the LGBTQ community.

Upwards of 77% of former conversion therapy participants report signifcant long-term psychological distress, according to the American Medical Association. LGBTQ youth who experience extreme rejection from their caregivers are eight times more likely to report a suicide attempt and six times more likely to report chronic depression, according to GLAAD. Furthermore, almost one in five transgender people claim they have been denied healthcare because of their gender identity.

Forced sexual orientation transformation efforts make LGBTQ youth indefinitely reliant on a medical system which is unequipped and unwilling to serve them.

This nation has invested more effort into forcing LGBTQ individuals to conform than acknowledging their humanity. We are now left with a system ill-equipped to provide equal access and service to all communities. The legislation currently moving through the Indiana General Assembly is the bare minimum.

Katelyn Balakir (she/her) is studying Policy Analysis and World Political Systems. She is a member of Indiana Model United Nations.

Excerpt from:
OPINION: Indiana might finally ban conversion therapy. That's too little, too late. - Indiana Daily Student

Is there a link between hypothyroidism and infertility? 5 lifestyle changes to manage thyroid disorders  |  Photo Credit: iStock Images

New Delhi: Hypothyroidism, or underactive thyroid, can make you feel unpleasant and affect many different systems in your body. In fact, a Harvard Medical School study reported that having even a slightly underactive thyroid may interfere with a womans ability to get pregnant. For women, treating this condition is a crucial part of any effort to improve fertility. Butlifestyle measures can help improve thyroid function and ease the symptoms of hypothyroidism.

Hypothyroidism is a medical condition in which your thyroid gland doesnt produce enough of certain crucial hormones. It occurs when the thyroid hormone regulations and production is disturbed and can lead to a wide range of issues like fatigue, low energy, weight gain, and constipation accompanied by infertility symptoms such as menstrual irregularity, difficulty in ovulation, and difficulty in conception.

The thyroid is a small butterfly-shaped gland in front of the neck which helps to regulate our hormones. The pituitary gland in the brain produces a hormone called thyroid-stimulating hormone which helps produce other two hormones known as triiodothyronine (T3) and thyroxine (T4) from the thyroid gland. These hormones aid in the normal functioning of the body.

Experts and medical doctors have known for some time that low levels of thyroid hormone can interfere with the release of an egg from the ovary (ovulation), which impairs fertility. Moreover, some of the underlying causes of hypothyroidism -such as certain autoimmune or pituitary disorders - may impair fertility, as per Mayo Clinic.

Even men suffer from hypothyroidism. In men, hypothyroidism can reduce the sperm volume and motility of sperm leading to decreased fertility. Ideally, anyone with a sedentary lifestyle and weight gain issues need to get their thyroid levels checked to rule out hypothyroidism, said Dr Richa Jagtap, clinical director & consultant - reproductive medicine, Nova IVF Fertility.

Hypothyroidism is commonly found alongside polycystic ovary syndrome (PCOS). There is a 2-4 per cent prevalence of hypothyroidism in women of the reproductive age group (20-40 years). Around 20-30 per cent of women with infertility may have hypothyroidism, added Dr Jagtap.

How to identify a thyroid problem

Once your doctor diagnoses the clinical symptoms, he or she will ask you to do a blood test called TSH or thyroid-stimulating hormone test and T3, T4 levels. Normal TSH levels fall between 0.5 to 4.5.

For a woman trying to conceive, even a mild increase in TSH should be appropriately corrected. This ideally needs to be corrected so that the TSH levels fall around the range of 2.5. These levels are safer for a woman to conceive because then her hormones will be in appropriate range while she is trying to get pregnant. The good news is that appropriate medication will help the thyroid hormones to get back to normal, added the doctor.

Usually, when one starts medication, it will take around 3 weeks for thyroid levels to start correcting. It also depends on how much the initial thyroid level was. For instance, if the TSH level is high then it will take a longer time to get back to the normal range. If it is borderline high then it wont take much time for the levels to get back to the recommended range. Lifestyle changes that can help manage thyroid disorders include:

Medication and lifestyle changes will help patients get back on track.If you are pregnant and have hypothyroidism, you mustget appropriate treatment. Also, you should not discontinue the medication without informing your doctor.

Disclaimer: Tips and suggestions mentioned in the article are for general information purposes only and should not be construed as professional medical advice. Always consult your doctor or a professional healthcare provider if you have any specific questions about any medical matter.

Read this article:
Is there a link between hypothyroidism and infertility? 5 lifestyle changes to manage thyroid disorders - Times Now

As a country, Japan is known for being at the forefront of technological advances, especially robotic tech. Japan has acted as the global leader in the revolution in robotics over the last several decades.

Bryan Brochu of rocketspace.com correctly notes that the island nation drives the advancement of artificial intelligence, machine learning, and machine vision technologies which are essential to powering the new age of innovation in robotic hardware.

Thus, it is no wonder that the newest and most innovative massage chair, the JPMedics Kawa Massage Chair, comes from the Japanese stable of innovative massage chair technology.

TheKawa Massage Chairincludes features such as:

At this juncture, it is reasonable to ask the question, why massage? Why is massage so important that massage chairs are designed to give expertly choreographed human-like massages?

The straightforward answer to this question is that massage is integral to maintaining human mental health and well-being, especially during the seemingly never-ending COVID-19 pandemic.

The Mayo Clinic reports that a sixty-minute massage lowers the stress hormone cortisol by 30% after one session. Additionally, a study titled Effectiveness of Therapeutic Massage for Generalized Anxiety Disorder: A Randomized Controlled Trial, reported that participants who underwent regular massage therapy for twelve weeks showed a 50% reduction in anxiety symptoms. And the 50% reduction in anxiety remained constant for over twenty-six weeks, even though the massage therapy had ended.

Lets take an in-depth look at some of the JPMedics Kawa features as a way to describe its health benefits to reduce stress and anxiety.

1. 3D humanistic massage mechanism

The 3D robotic engine moves along an extended L-track that reaches from the neck to the glutes. The 3D rollers move left, right, up, down, in, and out, mimicking the action of human hands, working deep into the shoulders and back, penetrating the shoulder and back muscles. The robotic engine plus the 3D rollers provides the most human-like massage found on any massage chair.

Lastly, a deep massage is designed to work out muscle knots, relax the muscles, and improve the blood flow to the areas massaged, helping the body relax and reduce stress and anxiety levels.

2. Air cell technology to position the body for an improved massage

The JPMedics Kawa massage chair uses air cell technology inside the chair to position the body for a more accurate and improved massage experience.

What is air cell technology?

In summary, air cell technology replaces the traditional foam inside the massage chairs back and seat with millions of individually constructed air pockets. These air pockets release air when weight bears down on them, acting as shock absorbers. And because these air pockets are separately built, they help spread the body weight evenly across the chair, resulting in increased blood circulation, the faster recovery of tired and tense muscles, and greater oxygen intake. When combined with a relaxing massage, this technology helps lower stress and anxiety levels, especially after a day plagued by low-grade anxiety and panic.

3. Foot rollers expertly massage the feet

The foot rollers supply a combination of pressure point massage and compression massage. Compression massage is when pressure is applied to the muscle or underneath of the foot in this instance. This pressure is held and released, facilitating relaxation and activation of the parasympathetic nervous system.

Juxtapositionally, pressure point massage is where direct pressure is applied to specific points on the foot, relieving muscle tension, and providing pain relief. Pressure point massage in the feet is also known as Reflexology, where pressure is applied to specific reflex points on the foot, triggering relaxation and healing of the corresponding organs and areas of the body.

In summary, the combination of Reflexology and compression massage on the feet relax the foot muscles and assists with stress and anxiety relief for the whole body.

Final Thoughts

There is no doubt that the information presented above shows that the JPMedics Kawa massage chair is a valuable purchase.

The Modern Back is the leading brick-n-click retailer in the United States, with the best and latest massage chairs are on offer both online and at The Modern Back's showrooms in Boynton Beach and Sarasota, Florida.

The company's virtual and land-based showrooms have the largest selection of massage chairs available for sale, including many different brands and models ofmassage chairsto suit every budget. Lastly, should clients require sales assistance, The Modern Back's friendly, knowledgeable staff are always on hand to answer questions and assist with their massage chair purchase.

Google Map Link: https://g.page/the-modern-back-boynton-beach?gm

Media ContactCompany Name: The Modern Back - Boynton BeachContact Person: Jessica HopeEmail: Send EmailPhone: 800-416-4304Address:1054 Gateway Blvd STE 108 City: Boynton BeachState: FL 33426Country: United StatesWebsite: https://themodernback.com

Original post:
JPMedics Kawa: The Newest Japanese Massage Chair and Its Health Benefits to Reduce Anxiety and Stress - Press Release - Digital Journal

Can you see this? Do you have to focus to read this text on your screen? Do you feel your eyesight is still strong or have your eyes deteriorated recently as well?

With the lockdown, homeschooling, and working from home, we are all staring at screens, tablets, and mobile phones even more than we already did before the COVID-19 pandemic. Most people spend endless amounts of time at home now and rarely go outside. But that means our eyes are constantly focused on objects in close range inside, and we're lacking the benefits of looking into the distance.

A lack of exercise is particularly noticeable in children including exercise for their eyes. Recent studies from the Netherlands and China show that as a result of COVID-19 restrictions, myopia has increased dramatically, especially in children. The phenomenon has been called "quarantine myopia".

Data from more than 120,000 Chinese school children showed that kids between the ages of six and eight were up to three times more likely to have myopia in 2020 than children of their age in previous years. In this age group, visual acuity shifted by a substantial 0.3 diopters towards myopia.

This drastic deterioration of eyesight in young children is particularly frightening because being nearsighted (not being able to see objects that are farther away) isdetermined at an early age. Once someone is nearsighted, they stay that way. In most cases, nearsightedness begins in primary school and it increases as children grow up. The earlier it starts, the more severe it becomes. The grown eye does not shrink again.

If the eyeball grows too much between the ages of six and 10, it means the child has a harder time seeing objects farther in the distance. Severe nearsightedness also increases the risk of retinal detachment, cataracts due to high pressure inside the eye, or even blindness later in life.

Focusing on objects in close range for too long can harm your eyesight

According to the Brien Holden Vision Institute, by the middle of the century around five billion people, or roughly half of the world's population, will be nearsighted. Especially in industrialized countries, the number of nearsighted people has risen rapidly in recent decades.

There is even a direct correlation between increased educational opportunities and poorer vision the higher the level of education, the higher the risk of myopia.

"The increase is mainly due to very early and intensive use of PCs, smartphones and tablets, combined with increasingly shorter amounts of time spent outdoors during the day," said Nicole Eter, Director of the Department of Ophthalmology at the University of Mnster.

Asian countries have above-average rates of nearsighted children and adolescents. For example, after World War II, about 20-30% of 20-year-olds in Hong Kong, Taiwan and South Korea were nearsighted; today the figure is more than 80%. In China, four out of five young people are now nearsighted. In other Asian countries, the rate is as high as 95%. In Europe too, about half of young adults are nearsighted.

Close to 85% of Chinese university students are nearsighted, raising the prospect of a significant swath of the country's population suffering loss of sight or blindness in old age

The risk of myopia can be reduced by not staring too long at an object in close range, regardless of whether it is a smartphone or an exciting book. The important factor is distance. The observer needs to look up regularly so that the gaze can wander into the distance.

The risk of myopia is reduced primarily by longer amounts of time spent outdoors, because daylight inhibits further growth of the eyeball. In enclosed rooms, the light intensity averages 300 to 500 lux (a measure of light levels), whereas on a bright summer day it can be around 100,000 lux outside. Studies from Scandinavia also show that myopia increases in the darker seasons, while it stagnates during brighter times of the year.

The blue light of smartphones robs us of sleep because it inhibits the release of the hormone melatonin.

Excessive use of electronic media does not justlead to more nearsightedness. It can also irritate, tire and dry out children's eyes. Constantly looking at screens also affects spatial awareness. Blurred vision or squinting can result from too much time spent on devices.

In addition, smartphone use in the evening may lead to sleep disorders.

"The high blue light content of the screens inhibits the release of the hormone melatonin, which makes you sleepy," explained Eter.

Although many devices now have a night mode that reduces the blue light, we should stop looking at them around two hours before bedtime.

Parents should limit their children's use of digital media, especially for the youngest age groups.

Parents should limit their children's screen time to help protect their eyesight

"From an ophthalmological point of view, PCs, smartphones and tablets are completely unsuitable for children up to the age of three," said Bettina Wabbels from the Bonn University Eye Clinic. The eye expert recommends daily use of no more than thirty minutes for four- to six-year-olds.

"At primary school age, media time of a maximum of one hour per day would be acceptable from an ophthalmological point of view, and up to two hours per day from the age of about ten," explained Wabbels.

However, her advice doesn't just apply to children and adolescents. Adults' eyes also need a break. So look up from the screen more often, let your eyes wander and spend more time outdoors.

Link:
COVID-19 and eyesight: Myopia on the rise during lockdown - DW (English)

A new womens health charity created by a Shelly Beach family is helping a whole generation of women find understanding, confidence and comfort as they undergo the change before the change.

The Debbie Gaunt Foundation was launched to build awareness about perimenopause, an often-challenging life event that can have devastating impacts on a womans physical and mental health.

The transitional period before a womans final menstrual period (menopause), perimenopause most commonly occurs in women in their mid-40s and signifies the ovaries winding down.

Lasting anywhere between one to ten years, women going through perimenopause often experience the same or even more intense symptoms of menopause.

Irregular periods, hot flushes and exhaustion are as common among perimenopausal women as they are during menopause, as are mood swings, anxiety and depression.

But unlike menopause, perimenopausal women often manage their condition independently and in private.

Medical research into health problems and complications linked to perimenopause is also surprisingly scant, something Foundation Founder, Craig Gaunt, became painfully aware of after losing his wife Debbie to suicide in 2019.

A wife, mother, friend and colleague, Debbie became severely mentally unwell shortly before her death, an episode that has since been partially attributed to the hormonal effects of perimenopause.

Vowing to honour Debbies memory to help other women and their families experiencing perimenopause, through the Debbie Gaunt Foundation, the Gaunt family now works tirelessly to raise awareness and understanding of perimenopause as well as funds for Australian led studies and projects that explore the mental health impacts of the condition.

Improving general awareness of perimenopause is also high atop the Foundations to do list.

Debbies perimenopause was very retrospective for my family.

We had never even heard of it before and sadly thats the case for most people, even women, so they just suffer throughout it all.

Thats why we made a promise to do something about it, Craig said.

The Foundations first major project has been to fund the development of a womens midlife mental health module for doctors to be delivered by Melbournes Monash Alfred Research Centre, the only specialised clinic in the country dedicated to helping women experiencing perimenopause.

The module will address perimenopausal depression, menopause and hormone replacement therapy, complex trauma disorder in perimenopause and family violence.

So far, the Foundation has donated $20,000 for the project and has committed to raising an additional $24,500 for it throughout 2021.

According to Craig, the Foundations long term goal is to help fund the opening of more specialist clinics like Monash Alfred around the country, including one here on the Coast.

Dilon Luke

Original post:
Debbie Gaunt Foundation putting perimenopause in the spotlight - Central Coast Community News

The medical group has locations throughout the Greater Los Angeles area and beyond.

LOS ANGELES (PRWEB) January 20, 2021

A December 18 article on 9Honey reports on a 27-year-old woman in New Zealand who was able to shed an astonishing 176 pounds after undergoing weight loss surgery. The patient, Claire Burt, said she battled eating disorders, depression, and isolation as a result of her excessive weight but was unable to slim down despite frequent dieting and medication. The article reports that Ms. Burt was finally able to receive gastric sleeve surgery in April when 80% of her stomach was removed. Ms. Burt stated that since the surgery, she hasnt faced any obsessive thoughts over food, and her mental state has significantly improved. Health and beauty medical center Beverly Hills Physicians says that losing weight and successfully keeping it off long term can be difficult to achieve naturally, and getting medical assistance for a healthier and better quality of life simply makes sense.

Beverly Hills Physicians says that, while most people have less weight to lose, what Ms. Burt experienced while attempting to lose weight on her own is exactly what many severely obese individuals face. The clinic says that, while it is possible for some people to lose weight naturally on their own, keeping the weight off is nearly always unsustainable because the body fights what it perceives as the threat of starvation. Beverly Hills Physicians says that, because the body becomes accustomed to receiving a certain number of calories every day, it sends hunger signals to the brain in an attempt to encourage the individual to eat more when that intake is significantly reduced.

The health and beauty medical group says that this is why medical intervention is often necessary to lose and maintain a healthy weight for those fighting obesity. By removing a portion of the stomach in such procedures as sleeve gastrectomy, the hormone center responsible for sending the hunger pangs is often minimized. In addition, Beverly Hills Physicians says that, with a drastically smaller stomach, patients are only able to eat smaller portions comfortably, further helping individuals maintain weight loss.

The bariatric center adds that when patients can lose a significant amount of weight, they are not only reducing the likelihood of developing health issues such as diabetes or cardiovascular disease, but they are also improving their overall quality of life. Mobility, energy levels, and more can all be subtle benefits of losing significant amounts of weight.

Readers interested in learning more about weight loss surgery or any other of Beverly Hills Physicians offerings can call 1-800-788-1416 or visit the health groups website at https://www.beverlyhillsphysicians.com/.

Share article on social media or email:

See the rest here:
Weight Loss Surgery Advantages Emphasized in New Zealand Woman's 175 Pound Weight Reduction, says Beverly Hills Physicians - PR Web